AmCad BioMed Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 15.71 million compared to TWD 13.26 million a year ago. Net loss was TWD 10.81 million compared to TWD 14.11 million a year ago. Basic loss per share from continuing operations was TWD 0.2 compared to TWD 0.27 a year ago.
For the nine months, sales was TWD 41.84 million compared to TWD 47.84 million a year ago. Net loss was TWD 34.41 million compared to TWD 33.32 million a year ago. Basic loss per share from continuing operations was TWD 0.65 compared to TWD 0.63 a year ago.